Zogenix — Corporate Update (July 2015)
7 slides from Zogenix's corporate update, Jul 14, 2015
Slide 1: ZX008 Development Update
1 NASDAQ: Exhibit 99.1 July 14 th , 2015 ZX008 Development Update Recent FDA correspondence (Type C meeting) clarified requirements for ZX008 IND and Phase 3 program
Slide 2: CMC and Non-Clinical Aspects
CMC and Non-Clinical Aspects 2 CMC • Drug substance synthetic pathway, starting material and validation strategy confirmed • General agreement with drug substance and drug product specification attributes – Phase 3 supplies: drug substance manufactured; liquid oral formulation manufactured and on st
Slide 3: Clinical and Regulatory Aspects
Clinical and Regulatory Aspects 3 Clinical • FDA agreed that Zogenix’s proposal of two double-blind, randomized, controlled Phase 3 studies plus one long-term, open label extension study should be sufficient to support registration, pending review of study outcomes • FDA favored a fixed, multiple-do
Slide 4: ZX008 Phase 3 Study Design
ZX008 Phase 3 Study Design ZX008 High dose ZX008 Low dose Placebo 4 8 WEEKS BASELINE OBSERVATION 12 WEEKS TREATMENT N = 105 Ages 2 – Two identical studies, one US and one multinational Q4 2015 initiation Open Label Safety Study Initial Screen
Slide 5: Pivotal Study Objectives
Pivotal Study Objectives 5 Efficacy Endpoints • Primary Endpoint – % change in convulsive seizures from baseline • Key Secondary Endpoints – Responder analysis (Primary endpoint for EU study) – Convulsive seizure-free interval • Other Secondary Endpoints – Episodes of status epilepticus – Caregiver
Slide 6: Back-up only
6 Back-up only
Slide 7: ZX008 Phase 3 Study Design Submitted to FDA
ZX008 Phase 3 Study Design Submitted to FDA Placebo Placebo ZX008 ZX008 2.5 mg, 5 mg, 10 mg 7 UP TO 28 DAYS 4 WEEKS BASELINE OBSERVATION 4-12 WEEKS TITRATION 12 WEEKS MAINTENANCE Titrate to Next Dose if <75% Reduction in Seizure Frequency N = 56 Ages 2 - Open Label Safety Study Option Screening